Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tislelizumab NCI Drug Dictionary]: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tislelizumab NCI Drug Dictionary]: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | ||
| Line 13: | Line 12: | ||
**[[Non-small cell lung cancer, squamous]] | **[[Non-small cell lung cancer, squamous]] | ||
| + | ==History of changes in NMPA indication== | ||
| + | *2019-12-26: Initial approval | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BGB-A317 | *'''Code name:''' BGB-A317 | ||
| + | *'''Generic name:''' tilelizumab | ||
| + | *'''Brand name:''' Baizean | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 28: | Line 31: | ||
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
| − | [[Category:NMPA approved | + | [[Category:NMPA approved in 2019]] |
Revision as of 02:22, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Bladder cancer
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
History of changes in NMPA indication
- 2019-12-26: Initial approval
Also known as
- Code name: BGB-A317
- Generic name: tilelizumab
- Brand name: Baizean
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Bladder cancer medications
- Esophageal cancer medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved in 2019